. 2022 Dec 9;12(6):6980–6993. doi: 10.1002/cam4.5495

TABLE 2.

Multivariate analysis of overall survival

	Univariate analysis			Multivariate analysis
				Model 1			Model 2
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Age (years)
<75 (n = 233)	1	0.989–2.061	0.057	1	1.013–2.197	0.043	1	0.995–2.137	0.053
≥75 (n = 188)	1.428	0.989–2.061	0.057	1.492	1.013–2.197	0.043	1.458	0.995–2.137	0.053
Sex
Female (n = 81)	1	0.588–1.467	0.750	1	0.523–1.352	0.474	1	0.599–1.535	0.860
Male (n = 340)	0.928	0.588–1.467	0.750	0.841	0.523–1.352	0.474	0.959	0.599–1.535	0.860
Etiology
Viral (n = 213)	1	0.790–1.643	0.848	1	0.669–1.432	0.912	1	0.593–1.282	0.486
Non‐viral (n = 208)	1.140	0.790–1.643	0.848	0.979	0.669–1.432	0.912	0.872	0.593–1.282	0.486
α‐fetoprotein (ng/mL)
<100 (n = 247)	1	1.602–3.373	<0.001	1	1.200–2.671	0.004	1	1.263–2.779	0.002
≥100 (n = 174)	2.325	1.602–3.373	<0.001	1.790	1.200–2.671	0.004	1.873	1.263–2.779	0.002
BCLC stage
≤B (n = 175)	1	1.100–2.459	0.015	1	0.751–1.815	0.492	1	0.766–1.848	0.440
≥C (n = 246)	1.645	1.100–2.459	0.015	1.167	0.751–1.815	0.492	1.190	0.766–1.848	0.440
Atez/Bev therapy type
First line (n = 259)	1	0.811–1.698	0.396	1	0.642–1.380	0.755	1	0.615–1.340	0.626
Other (n = 162)	1.173	0.811–1.698	0.396	0.941	0.642–1.380	0.755	0.908	0.615–1.340	0.626
NLR
<3 (n = 247)	1	1.438–3.027	<0.001	1	1.055–2.358	0.026	1	1.149–2.548	0.008
≥3 (n = 163)	2.087	1.438–3.027	<0.001	1.578	1.055–2.358	0.026	1.711	1.149–2.548	0.008
GPS
0 (n = 239)	1			1
1 (n = 130)	2.087	1.370–3.180	<0.001	1.711	1.106–2.646	0.016
2 (n = 52)	4.957	3.066–8.014	<0.001	4.643	2.778–7.762	<0.001
Neo‐GPS
0 (n = 132)	1						1
1 (n = 212)	3.335	1.898–5.861	<0.001				3.038	1.715–5.383	<0.001
2 (n = 77)	6.249	3.414–11.440	<0.001				5.312	2.853–9.890	<0.001

Abbreviations: Atez/Bev, atezolizumab plus bevacizumab; BCLC, Barcelona Clinic Liver Cancer; GPS, Glasgow prognostic score; LR, neutrophil‐to‐lymphocyte ratio.